Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verastem, Inc. (VSTM) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including Forms 8-K, 10-K, 10-Q, and registration statements filed with the U.S. Securities and Exchange Commission. Verastem’s filings document its status as a Nasdaq-listed biopharmaceutical issuer focused on RAS/MAPK pathway-driven cancers, with common stock registered on The Nasdaq Capital Market under the symbol VSTM.
Recent Form 8-K reports highlight several important areas for investors: underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement on Form S-3, preliminary and updated clinical data for the KRAS G12D inhibitor VS-7375, and company communications regarding AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. These current reports also reference updated corporate presentations and conference materials that outline Verastem’s pipeline and strategy.
For a biopharmaceutical company like Verastem, periodic reports such as Forms 10-K and 10-Q (when available) typically contain detailed information on research and development spending, commercialization activities for AVMAPKI FAKZYNJA CO-PACK, risk factors related to oncology drug development, and the status of key clinical programs such as RAMP 301, RAMP 205, and VS-7375-101. Capital structure changes, including equity offerings and warrant terms, are also described in registration statements and accompanying exhibits.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain complex sections in plain language, highlight material events, and surface items of interest such as financing transactions, clinical trial disclosures, and changes in capital markets activity. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks for Verastem, review details of public offerings and warrant structures, and explore how regulatory filings align with the company’s oncology pipeline and commercial strategy.
Verastem (VSTM) furnished an update on its VS-7375 Phase 1/2a trial in KRAS G12D mutant solid tumors, reporting preliminary safety and early activity signals from the first two monotherapy dose levels. The company cleared 400 mg QD and 600 mg QD with no dose-limiting toxicities. Among five efficacy-evaluable patients with at least one scan, four had tumor reduction and remain on treatment.
The safety profile in PDAC and NSCLC was consistent with data from partner GenFleet (GFH375), which selected 600 mg QD as its recommended Phase 2 dose in China. Verastem has begun enrollment for a dose-escalation combination cohort with cetuximab in advanced solid tumors, including colorectal cancer, and is continuing monotherapy escalation to 900 mg QD before selecting a recommended Phase 2 dose. An interim safety and efficacy update is planned in the first half of 2026. VS-7375 entered U.S. Phase 1/2a after IND clearance in April 2025 and trial initiation in June 2025.
Verastem (VSTM) reported updated Phase 1/2 data for VS-7375 (GFH375) monotherapy in advanced KRAS G12D mutant pancreatic ductal adenocarcinoma from a China study run by partner GenFleet. Among 59 efficacy‑evaluable patients as of September 27, 2025, the overall response rate was 40.7% (24/59) and the disease control rate was 96.7% (57/59) at a daily dose of 600 mg. 91.5% of patients had reductions in target lesions. Four‑month overall survival observed was 92.2%; median OS was not reached with a median follow‑up of 5.65 months. Median progression‑free survival was 5.52 months, and 31 patients (47%) remained on treatment, with the longest duration reaching 367 days.
Safety (cutoff August 27, 2025) was consistent with prior reports. Grade 3 treatment‑related adverse events occurred in 30.3% and Grade 4 in 1.5%; 6.1% had dose reductions and 3% discontinued due to TRAEs. Mean relative dose intensity was 93%. The U.S. IND for VS‑7375 was cleared in April 2025, and a Phase 1/2a trial began in June 2025.
Verastem, Inc. (VSTM): Director insider sale filed on Form 4. On 10/09/2025, the reporting person, a director, sold 8,333 shares of common stock in open-market transactions at a weighted average price of $9.06 per share under a Rule 10b5-1 trading plan. The trades occurred across prices ranging from $8.70 to $9.33. Following the transaction, the reporting person directly owned 8,333 shares.
Verastem, Inc. reports a Form 144 notice for a proposed sale of 8,333 common shares previously received as a restricted stock grant on
Insider sale to cover tax withholding: Verastem, Inc. CFO Daniel Calkins reported two small sales of common stock tied to restricted stock unit vesting. On 09/22/2025 he sold 57 shares at $9.08 and on 09/24/2025 he sold 25 shares at $9.23, reducing his beneficial ownership from 109,920 to 109,838 shares. The Form 4 states these sales were made to satisfy statutory withholding obligations associated with RSU vesting, not an open-market disposition for other purposes.
Brian M. Stuglik, a director of Verastem, Inc. (VSTM), reported a sale of 587 shares of common stock on 09/16/2025 at $9.99 per share. The filing states the shares were sold to satisfy statutory withholding obligations arising from the vesting of restricted stock units. After the transaction, the reporting person beneficially owns 101,739 shares in a direct capacity. The Form 4 indicates it was filed by one reporting person and includes an explanatory note that the disposition was for tax withholding tied to RSU vesting.
Verastem, Inc. (VSTM) director Robert E. Gagnon reported a sale of 281 shares of common stock on 09/16/2025 at a price of $9.99 per share, reducing his direct holdings to 41,961 shares. The filing states the shares were sold solely to satisfy statutory withholding for vested restricted stock units. The Form 4 was signed by an attorney-in-fact on 09/18/2025. No options, warrants, or other derivative transactions are reported in this filing.
Insider sale to satisfy tax withholding — The Form 4 shows reporting person Paterson Dan, identified as Verastem, Inc. (VSTM) Director and President and CEO, reported a transaction dated 09/16/2025. The filing discloses a sale of 390 shares of common stock at $9.99 per share, executed to satisfy statutory withholding related to the vesting of restricted stock units. After the sale, the reporting person beneficially owned 442,117 shares directly. The form was signed by an attorney‑in‑fact on 09/18/2025. The filing contains no other transactions, derivatives, or additional explanatory items.
Verastem, Inc. submitted an 8-K reporting a material event: the company furnished a Corporate Presentation dated
Form 144 filed for Verastem, Inc. (VSTM) reporting a proposed sale of 31,790 common shares through Raymond James & Associates on 09/17/2025 on NASDAQ with an aggregate market value of $310,429.00. The filing lists total shares outstanding of 63,043,373. The securities were acquired as compensation (RSUs) in multiple grants between 03/11/2013 and 12/31/2021, with individual grant sizes shown (for example, 9,532 shares on 12/31/2020 and 9,216 on 08/11/2021). The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
FAQ
What is the current stock price of Verastem (VSTM)?
What is the market cap of Verastem (VSTM)?
